Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 250 versus METATENSIN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 250 versus METATENSIN 4.
DIUPRES-250 vs METATENSIN #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
None Documented
None Documented
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination